{
    "id": 687,
    "name": "hepatoblastoma",
    "source": "DOID",
    "definition": null,
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:687",
    "evidence": [
        {
            "id": 6229,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a human hepatoblastoma cell line was sensitive to UAB30 in both culture and in xenograft models, demonstrating cell-cycle arrest, decreased cell proliferation, and reduced tumor growth (PMID: 26873726).",
            "molecularProfile": {
                "id": 17605,
                "profileName": "Unknown unknown"
            },
            "therapy": {
                "id": 4098,
                "therapyName": "UAB30",
                "synonyms": null
            },
            "indication": {
                "id": 687,
                "name": "hepatoblastoma",
                "source": "DOID"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 5496,
                    "pubMedId": 26873726,
                    "title": "Preclinical Evaluation of UAB30 in Pediatric Renal and Hepatic Malignancies.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26873726"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 15230,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD1208 treatment of hepatoblastoma cell lines and xenografts, overexpressing Pim3, resulted in decreased proliferation, migration, invasion, and tumor growth (PMID: 29854306).",
            "molecularProfile": {
                "id": 18334,
                "profileName": "PIM3 over exp"
            },
            "therapy": {
                "id": 3224,
                "therapyName": "AZD1208",
                "synonyms": null
            },
            "indication": {
                "id": 687,
                "name": "hepatoblastoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 12928,
                    "pubMedId": 29854306,
                    "title": "Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29854306"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        {
            "nctId": "NCT00980460",
            "title": "Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer",
            "phase": "Phase III",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 2298,
                    "therapyName": "Irinotecan + Temsirolimus + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 2297,
                    "therapyName": "Cisplatin + Fluorouracil + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 1009,
                    "therapyName": "Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01331135",
            "title": "Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors",
            "phase": "Phase I",
            "recruitment": "Active, not recruiting",
            "therapies": [
                {
                    "id": 917,
                    "therapyName": "Sirolimus",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT01956669",
            "title": "Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors",
            "phase": "Phase II",
            "recruitment": "Completed",
            "therapies": [
                {
                    "id": 848,
                    "therapyName": "Pazopanib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT02867592",
            "title": "Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 998,
                    "therapyName": "Cabozantinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03155620",
            "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2683,
                    "therapyName": "Tazemetostat",
                    "synonyms": null
                },
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                },
                {
                    "id": 1069,
                    "therapyName": "LY3023414",
                    "synonyms": null
                },
                {
                    "id": 342,
                    "therapyName": "Vemurafenib",
                    "synonyms": null
                },
                {
                    "id": 850,
                    "therapyName": "Palbociclib",
                    "synonyms": null
                },
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                },
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                },
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                },
                {
                    "id": 913,
                    "therapyName": "Selumetinib",
                    "synonyms": null
                },
                {
                    "id": 961,
                    "therapyName": "Ensartinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03210714",
            "title": "Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1028,
                    "therapyName": "Erdafitinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03213678",
            "title": "PI3K/mTOR Inhibitor LY3023414 in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 1069,
                    "therapyName": "LY3023414",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03213704",
            "title": "Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 2650,
                    "therapyName": "Larotrectinib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03233204",
            "title": "Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 837,
                    "therapyName": "Olaparib",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03533582",
            "title": "Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 8240,
                    "therapyName": "Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 6946,
                    "therapyName": "Cisplatin + Doxorubicin + Fluorouracil + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 8242,
                    "therapyName": "Carboplatin + Cisplatin + Doxorubicin + Etoposide",
                    "synonyms": null
                },
                {
                    "id": 8241,
                    "therapyName": "Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine",
                    "synonyms": null
                },
                {
                    "id": 700,
                    "therapyName": "Cisplatin",
                    "synonyms": null
                },
                {
                    "id": 6951,
                    "therapyName": "Cisplatin + Doxorubicin + Sorafenib",
                    "synonyms": null
                },
                {
                    "id": 6947,
                    "therapyName": "Cisplatin + Doxorubicin",
                    "synonyms": null
                },
                {
                    "id": 8243,
                    "therapyName": "Carboplatin + Cisplatin + Doxorubicin",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03654716",
            "title": "Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer",
            "phase": "Phase I",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 4755,
                    "therapyName": "ALRN-6924 + Cytarabine",
                    "synonyms": null
                },
                {
                    "id": 2273,
                    "therapyName": "ALRN-6924",
                    "synonyms": null
                }
            ]
        },
        {
            "nctId": "NCT03698994",
            "title": "Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)",
            "phase": "Phase II",
            "recruitment": "Recruiting",
            "therapies": [
                {
                    "id": 997,
                    "therapyName": "Ulixertinib",
                    "synonyms": null
                }
            ]
        }
    ]
}